Phase 1 Study of Vorinostat as a Radiation Sensitizer with (131)I-Metaiodobenzylguanidine ((131)I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma

PURPOSE: (131)I-metaiodobenzylguanidine (MIBG) is a radiopharmaceutical with activity in neuroblastoma. Vorinostat is a histone deacetylase inhibitor that has radiosensitizing properties. The goal of this phase 1 study was to determine the maximum tolerated doses of vorinostat and MIBG in combinatio...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Cancer Res
Hauptverfasser: DuBois, Steven G., Groshen, Susan, Park, Julie R., Haas-Kogan, Daphne A., Yang, Xiaodong, Geier, Ethan, Chen, Eugene, Giacomini, Kathy, Weiss, Brian, Cohn, Susan L., Granger, M. Meaghan, Yanik, Gregory A., Hawkins, Randall, Courtier, Jesse, Jackson, Hollie, Goodarzian, Fariba, Shimada, Hiroyuki, Czarnecki, Scarlett, Tsao-Wei, Denice, Villablanca, Judith G., Marachelian, Araz, Matthay, Katherine K.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2015
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4470833/
https://ncbi.nlm.nih.gov/pubmed/25695691
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-3240
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge